Study of Arsenic Sulfide in Solid Tumor Cells Reveals Regulation of Nuclear Factors of Activated T-cells by PML and p53

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Ding, Wenping ^a   Tong, Yingying ^a   Zhang, Xiuli ^a   Pan, Minggui ^b,c   Chen, Siyu ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b KAISER PERMANENTE   (United States)

^c DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRISULFIDE; CYCLOSPORIN; MESSENGER RNA; MYC PROTEIN; ORGANOARSENIC DERIVATIVE; PML PROTEIN, HUMAN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; SULFIDE; TRANSCRIPTION FACTOR NFAT;

BIOLOGICAL MODEL; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; COLON TUMOR; DOWN REGULATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETICS; HCT 116 CELL LINE; HUMAN; METABOLISM; PATHOLOGY; PROMOTER REGION;

ARSENICALS; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLOSPORINE; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HUMANS; MODELS, BIOLOGICAL; NFATC TRANSCRIPTION FACTORS; PROMOTER REGIONS, GENETIC; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; SULFIDES; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955452737     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19793     Document Type: Article

References (34)

1. Shen Z. X. et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 101, 5328-35 (2004).
2. Chen, S. J. et al. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 117, 6425-6437 (2011).
3. th).
4. Emadi, A. & Gore, S. D. Arsenic Trioxide - An Old Drug Rediscovered. Blood 24, 191-199, doi: 10.1016/j.blre.2010.04.001 (2010).
5. Zhang, X. W. et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328, 240-243 (2010).
6. 4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc Natl Acad Sci USA 107, 21683-21688 (2010).
7. Platanias, L. C. Biological responses to arsenic compounds. J Biol Chem 284, 18583-18587 (2009).
8. Guo, A. et al. The function of PML in p53-dependent apoptosis. Nat Cell Biol 2, 730-736 (2000).
9. Bernardi, R. et al. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Bio 6, 665-672 (2004).
10. Pearson, M. et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406, 207-210 (2000).
11. de Stanchina, E. et al. PML is a direct p53 target that modulates p53 effector functions. Mol Cell 13, 523-535 (2004).
12. Joe, Y. et al. ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis. J Biol Chem 281, 28764-28771 (2006).
13. Crabtree, G. R. & Olson, E. N. NFAT signaling: choreographing the social lives of cells. Cell 109, S67-79 (2002).
14. Graef, I. A., Chen, F., Chen, L., Kuo, A. & Crabtree G. R. Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 105, 863-875 (2001).
15. Winslow, M. M. et al. Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev Cell 10, 771-782 (2006).
16. Pan, M. G., Xiong, Y. & Chen, F. NFAT gene family in inflammation and cancer. Curr Mol Med 13, 543-554 (2013).
17. Buchholz, M. et al. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J 15, 3714-3724 (2006).
18. Koenig, A. et al. NFAT-induced histone acetylation relay switch promotes c-Myc-dependent growth in pancreatic cancer cells. Gastroenterology 138, 1189-1199.e1-2 (2010).
19. Gregory, M. A. et al. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 18, 84-87 (2010).
20. Foldynova-Trantirkova, S. et al. Breast cancer-specific mutations in CK1 epsilon inhibit Wnt/beta-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration. Breast Cancer Res 12, R30 (2010).
21. Courtwright, A. et al. Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway. Cancer Res 69, 4621-4628 (2009).
22. Robbs, B. K., Cruz, A. L., Werneck, M. B., Mognol, G. P. & Viola, J. P. Dual roles for NFAT transcription factor genes as oncogenes and tumor suppressors. Mol Cell Biol 28, 7168-7181 (2008).
23. Glud, S. Z. et al. A tumor-suppressor function for NFATc3 in T-cell lymphomagenesis by murine leukemia virus. Blood 106, 3546-3552 (2005).
24. Lo, Y. H., Wu, C. C., Shih, H. M. & Lai, M. Z. Selective activation of NFAT by promyelocytic leukemia protein. Oncogene 27, 3821-3830 (2008).
25. Komarov, P. G. et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285, 1733-1737 (1999).
26. Menendez, D., Unga, A. & Resnick, M. A. The expanding universe of p53 targets. Nat Rev Cancer 9, 724-737 (2009).
27. Contente, A., Dittmer, A., Koch, M. C., Roth, J. & Dobbelstein, M. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat. Genet. 30, 315-320 (2002).
28. el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W. & Vogelstein, B. Definition of a consensus binding site for p53. Nat Genet 1, 45-49 (1992).
29. Zheng, J. et al. Negative cross talk between NFAT1 and Stat5 signaling in breast cancer. Mol Endocrinol 25, 2054-2064 (2011).
30. Tripathi, M. K. et al. Nuclear factor of activated T-cell activity is associated with metastatic capacity in colon cancer. Cancer Res 74, 6947-6957 (2014).
31. 4 combined with JQ1, cisplatin, or celecoxib inhibit gastric and colon cancer cell growth. Drug Des Devel Ther 9, 5851-5862, doi: 10.2147/DDDT.S92943 (2015).
32. Naito, S., von Eschenbach, A. C., Giavazzi, R. & Fidler I. J. Growth and metastasis of tumor cells from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 46, 4109-4115 (1986).
33. Ma, Y., Ma, L., Guo, Q. & Zhang, S. Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients. J Exp Clin Cancer Res 29, 85 (2010).
34. Hirsch, F. R. et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 22, 3646-3654 (2003).